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cases was low. Acute grade II-IV GVHD developed in
17.8% of the patients, most cases of chronic GVHD
were limited, and the 4 patients with extensive chronic
GVHD (17.4% of the patients surviving to day 100)
were not severe, did not require prolonged treatment
and never developed serious infections. Other groups
have demonstrated the beneﬁcial effect of THY in
reducing the incidence of acute and chronic GVHD
after unrelated SCT [2-5,7]. With a median follow-up
similar to our study, the GITMO group showed a
39% incidence of extensive chronic GVHD in recip-
ients of unrelated SCT after the administration of 7.5
or 15 mg/kg THY, with the last dose infused on day
3 or 2 [7]. The patients receiving 15 mg/kg THY
also had the lowest incidence of severe acute GVHD,
not translating into a survival beneﬁt because of a high
rate of fatal infections [7].
Despite the use of 25 mg/kg THY, we did not
observe a high incidence of relapse. We hypothesize
that the early discontinuation of cyclosporine and my-
cophenolate mofetil posttransplant may have contrib-
uted for the emergence of controllable GVHDwith the
development of a graft-versus-leukemia effect, thus com-
pensating for the early in vivo donor T cell depletion
mediated by THY. Overall, this translated into a survival
beneﬁt for the patients with chronic GVHD.
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Bortezomib after
Allografting in Multiple
Myeloma: Association
between Neurotoxicity
and Cyclosporine
Treatment
Relapse following allografting in patients with
multiple myeloma (MM) remains relatively high
[1,2]. The observations of a possible pivotal role of
NF-B in graft-versus-host disease and the efﬁcacy
of bortezomib in refractory/relapsed MM through
the inhibition of NF-B have provided the rationale
for using this new agent in relapsed MM following
allografting [3-9]. We focused on bortezomib-in-
duced neurotoxicity in 24 relapsed patients following
nonmyeloablative/reduced intensity allografting. Nine-
teen were partly described in an earlier report in the
Haematologica/Hematology Journal [8]. Conditioning
regimens were 2 Gy total body irradiation (TBI) based
(n  19) or a combination of thiotepa, cyclophosph-
amide, and melphalan (n  5) [1,8]. Donors were
human leukocyte antigen (HLA) identical siblings
(n  22) or unrelated (n  2). Postgrafting immuno-
suppression consisted of cyclosporine with mycophe-
nolate mofetil or methotrexate. Bortezomib was ad-
ministered after a median of 20 months from
allografting (range 5-54), at ﬁrst (n  6) or second
relapse (n  10), or beyond second relapse (n  8).
Patients received bortezomib 1.0 (n 8) or 1.3 mg/m2
(n  16) on days 1, 4, 8, and 11 every 3 weeks for a
median of 3 courses (1-8), alone (n  5) or in combi-
nation with steroids (n  19). Informed consent was
obtained on enrollment according to the institutional
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review boards of the participating centers. Overall,
bortezomib toxicity was observed in 17 of 24 patients
(71%) including thrombocytopenia (8 of 24; 33%),
neutropenia (2 of 24; 8%), and rash (1 of 24; 4%) [3].
However, incidence and severity of peripheral neu-
ropathy were far higher than that currently reported
in nontransplant patients: 14 of 24 (58%) including 7
of 24 (29%) with grade III-IV [3]. Importantly, 6
required bortezomib discontinuation because of se-
vere neuropathy unresponsive to dose reduction. An-
other patient suspended treatment because of severe
thrombocytopenia. Interestingly, the only factor sig-
niﬁcantly associated with the development of severe
neurotoxicity was prolonged treatment, median 15
months, with cyclosporine (Table 1). Moreover, al-
though statistical signiﬁcance was not reached, severe
neurologic side effects occurred more frequently in
patients (6 of 7) on the higher bortezomib dose.
The mechanisms of drug-induced neural damage
remains unclear for many drugs and may result from
several factors. Cyclosporine, a calcineurin inhibitor,
is characterized by neurotoxic effect on both sensorial
and motoric functions as well as on the central ner-
vous system. Its toxicity has been associated with met-
abolic changes, microvascular, and assonal damage
[10]. Prolonged cyclosporine treatment may have re-
sulted in a subclinical damage that became clinically
relevant with the administration of bortezomib. Con-
versely, we did not observe any correlation between
neurotoxicity and previous thalidomide treatment.
This may suggest different causal mechanisms of tha-
lidomide neurotoxicity from those of bortezomib.
Overall disease response, evaluated in 18 patients
after at least 2 bortezomib courses, was 72%, includ-
ing 5 complete (CR) and 8 partial remissions (PR).
After a median follow-up of 13 months (4-27) from
the start of treatment, 7 patients had died from disease
progression and 3 patients were alive in continuous
response.
In summary, clinicians should be aware of the risk
of severe neurotoxicity associated with bortezomib
after prolonged cyclosporine treatment. Up-front dose
reduction in the treatment schedule may be consid-
ered in these patients.
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Table 1. Post-allografting Bortezomib and Neurotoxicity: Analysis of Risk Factors
Peripheral neuropathy Grade 0-2 Grade 3-4 P
Concomitant steroid therapy 15/17 5/7 .9*
>1 treatment line from postgrafting relapse to bortezomib 7/17 1/7 .3*
Previous treatment with thalidomide 9/17 5/7 .3*
Months from diagnosis to bortezomib, median (range) 34 (19-164) 31 (21-74) .6†
Months of cyclosporine treatment, median (range) 6 (328) 15 (6-37) .02†
*Fisher exact test; †two-sample t-test.
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